CG ONCOLOGY INC (CGON) Stock News

USA - Nasdaq - NASDAQ:CGON - US1569441009 - Common Stock

43.25 USD

-1.59 (-3.55%)

Last: 12/1/2025, 6:17:56 PM

43 USD

-0.25 (-0.58%)

After Hours: 12/1/2025, 6:17:56 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CGON Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: CG Oncology Inc.

CG Oncology Announces New Board Member and Board Transition

5 days ago - By: CG Oncology Inc.

CG Oncology Announces New Board Member and Board Transition

6 days ago - By: CG Oncology Inc.

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting

6 days ago - By: CG Oncology Inc.

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting

14 days ago - By: Zacks Investment Research - Mentions: NU SR GLOB

Company News for Nov 17, 2025

14 days ago - By: The Motley Fool - Mentions: AMLX ABVX COGT CNTA

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead

14 days ago - By: The Motley Fool - Mentions: LQDA ABVX COGT AMLX ...

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch

3 months ago - By: Benzinga

CG Oncology Stock Signals Bullish Momentum Ahead

17 days ago - By: Zacks Investment Research - Mentions: IMTX

CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates

17 days ago - By: CG Oncology Inc.

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

17 days ago - By: CG Oncology Inc.

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

5 months ago - By: Benzinga

Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock

3 months ago - By: CG Oncology Inc.

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

3 months ago - By: CG Oncology Inc.

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

3 months ago - By: CG Oncology Inc.

CG Oncology Completes Enrollment in PIVOT-006

3 months ago - By: CG Oncology Inc.

CG Oncology Completes Enrollment in PIVOT-006

3 months ago - By: CG Oncology Inc.

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

3 months ago - By: CG Oncology Inc.

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

4 months ago - By: CG Oncology Inc.

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

4 months ago - By: CG Oncology Inc.

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

4 months ago - By: Zacks Investment Research - Mentions: ABUS

Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

4 months ago - By: Yahoo Finance

CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial

4 months ago - By: CG Oncology Inc.

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

4 months ago - By: CG Oncology Inc. - Mentions: ANIP

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals